PDS Biotechnology Co. (NASDAQ:PDSB) Short Interest Down 17.3% in March

PDS Biotechnology Co. (NASDAQ:PDSB) saw a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 3,860,000 shares, a decrease of 17.3% from the February 28th total of 4,670,000 shares. Currently, 11.4% of the company’s stock are short sold. Based on an average daily trading volume, of 614,400 shares, the short-interest ratio is currently 6.3 days.

Analysts Set New Price Targets

Separately, HC Wainwright dropped their target price on PDS Biotechnology from $21.00 to $13.00 and set a “buy” rating on the stock in a research report on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $9.00.

PDS Biotechnology Stock Up 6.9 %

PDSB traded up $0.08 during trading on Wednesday, hitting $1.16. The company had a trading volume of 256,147 shares, compared to its average volume of 526,006. PDS Biotechnology has a 1-year low of $1.06 and a 1-year high of $4.42. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.84 and a quick ratio of 2.84. The company has a market cap of $44.11 million, a PE ratio of -1.00 and a beta of 1.68. The business has a 50-day moving average of $1.39 and a 200-day moving average of $2.12.

PDS Biotechnology (NASDAQ:PDSB) last released its earnings results on Thursday, March 27th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.08. As a group, analysts forecast that PDS Biotechnology will post -1.2 earnings per share for the current year.

Institutional Trading of PDS Biotechnology

Several institutional investors and hedge funds have recently bought and sold shares of PDSB. Marshall Wace LLP increased its holdings in shares of PDS Biotechnology by 38.4% in the 4th quarter. Marshall Wace LLP now owns 39,024 shares of the company’s stock valued at $64,000 after acquiring an additional 10,837 shares during the last quarter. Raymond James Financial Inc. acquired a new position in PDS Biotechnology in the fourth quarter worth $26,000. Jane Street Group LLC bought a new stake in PDS Biotechnology during the fourth quarter valued at $58,000. Blair William & Co. IL raised its holdings in shares of PDS Biotechnology by 29.4% during the fourth quarter. Blair William & Co. IL now owns 157,500 shares of the company’s stock worth $257,000 after purchasing an additional 35,757 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of PDS Biotechnology by 9.8% in the 3rd quarter. Geode Capital Management LLC now owns 415,113 shares of the company’s stock worth $1,586,000 after buying an additional 37,142 shares during the last quarter. Institutional investors and hedge funds own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.